An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different...

Area of Science:

• Pharmacology
• Reproductive Health
• Drug Metabolism

Background:

• Levonorgestrel is a progestin used in various contraceptive formulations.
• Understanding levonorgestrel pharmacokinetics is crucial for assessing contraceptive efficacy and safety.
• Different administration routes result in varying systemic drug exposure.

Purpose of the Study:

• To compare the pharmacokinetics (PK) of levonorgestrel across multiple contraceptive methods.
• To develop a comprehensive population PK model for levonorgestrel.
• To analyze levonorgestrel exposure and variability based on administration route.

Main Methods:

• Integrated population pharmacokinetic (PK) analysis of data from 10 clinical pharmacology studies.
• Development of a comprehensive population PK model for levonorgestrel.
• Comparison of PK parameters for 6 levonorgestrel-containing contraceptives: 3 IUSs, 2 oral contraceptives, and 1 implant.

Main Results:

• Combined oral contraceptives resulted in the highest levonorgestrel exposure, followed by progestin-only pills and implants (similar exposure).
• Intrauterine systems (IUSs) demonstrated the lowest systemic levonorgestrel concentrations, with decreasing exposure from LNG-IUS 20, LNG-IUS 12, to LNG-IUS 8.
• In vivo release rates were highest for the implant, followed by LNG-IUS 20, LNG-IUS 12, and lowest for LNG-IUS 8, aligning with total levonorgestrel concentrations.

Conclusions:

• Levonorgestrel pharmacokinetics vary significantly based on the contraceptive administration route.
• IUSs provide localized delivery with substantially lower systemic levonorgestrel exposure compared to oral or implant methods.
• The developed population PK model provides a comprehensive understanding of levonorgestrel exposure and variability across different contraceptive products.